Can I read Activity of The Novel Kif18a Inhibitor Atx 295 Is Enriched in Whole Genome Doubled Ovarian Cancer Pre Clinical Models on EtoBox?
Activity of The Novel Kif18a Inhibitor Atx 295 Is Enriched in Whole Genome Doubled Ovarian Cancer Pre Clinical Models by lvran18001375360 is a document available to read on EtoBox.
What is Activity of The Novel Kif18a Inhibitor Atx 295 Is Enriched in Whole Genome Doubled Ovarian Cancer Pre Clinical Models about?
ATX-295 is a potent and selective inhibitor of KIF18A, showing significant anti-tumor activity in chromosomally instable (CIN) ovarian cancer models. The compound induces mitotic arrest and apoptosis selectively in CIN+ cells, with whole genome doubling serving as a predictive marker for sensitivity. A large cell panel screen indicates potential for KIF18A inhibition across various solid tumor types with high CIN, including ovarian, breast, and lung cancers.
- Author
- lvran18001375360
- Language
- EN